



Drug Coverage Decision for BC PharmaCare

About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

Details of Drug Reviewed

Drug	cladribine
Brand name	Mavenclad®
Dosage form	10 mg tablets
Manufacturer	EMD Serono
Submission type	Modification of Criteria
Indication reviewed	For the treatment of adult patients with relapsing-remitting multiple sclerosis
Canada’s Drug Agency (CDA-AMC) Reimbursement Reviews	The Formulary Management Expert Committee (FMEC) recommended: to Reimburse with clinical criteria and/or conditions. Visit the CDA-AMC website for more details .
Ministry of Health (Ministry) Initiated Review	The Ministry reviewed clinical and pharmacoeconomic combined reports prepared by the CDA-AMC’s Clinical Reimbursement Review (CRR) and Final FMEC Recommendation, including input from 2 patients, a clinician group, and BC clinician inputs, and a budget impact assessment (BIA).
Drug Coverage Decision	Limited Coverage benefits with modification of criteria for first-line treatment of adult patient with RRMS. Visit the Special Authority webpage for more details . This supersedes the drug decision summary for cladribine that was listed on January 25, 2022.
Date	April 22, 2026
Reasons	Drug coverage decision is consistent with the FMEC recommendation that cladribine be reimbursed for the first-line treatment of adult patients with RRMS.

- Cladribine demonstrated some advantages over comparators (e.g., glatiramer acetate, interferon beta-1a and 1b, and teriflunomide) with respect to preventing MS related relapses.
- The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer which were able to address the concerns identified by the CDEC with respect to the cost-effectiveness and value for money.

The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent national organization called Canada's Drug Agency (CDA-AMC) provides evidence-based recommendations to public drug plans across Canada through its reimbursement review process. As part of the CDA-AMC's Clinical Reimbursement Review process, the Canadian Drug Expert Committee (CDEC) makes reimbursement recommendations for non-oncology pharmaceuticals to the participating federal, provincial, and territorial publicly funded drug plans. In developing its recommendations, the CDEC considers:

- whether the drug is safe and effective
- what the drug costs and whether funding it provides good value
- ethical considerations of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by considering:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the CDA-AMC
- the recommendations and reimbursement conditions of the CDEC
- if a Ministry Initiated review, the advice of an independent expert group called the Drug Benefit Council (DBC)
- BC-specific patient input collected through the Your Voice website
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.